Catharanthalog

Catharanthalog (CAG) is a non-hallucinogenic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid catharanthine but with a simplified chemical structure.^[1][2] It is known to act as a serotonin 5-HT_2A receptor partial agonist.^[2] The drug produces analgesic-like effects in a neuropathic pain model in rodents that can be reduced by the serotonin 5-HT_2A receptor antagonist ketanserin.^[2] Catharanthalog is said to have relatively low blood–brain barrier permeability owing to relatively low lipophilicity.^[2] It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.^[2] The drug was first described in the scientific literature by 2025.^[1][2]

Catharanthalog

Clinical data
Other names	CAG
Drug class	Non-hallucinogenic serotonin 5-HT2A receptor partial agonist
ATC code	None
Identifiers
IUPAC name methyl 3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole-5-carboxylate
CAS Number	2973762-95-5
PubChem CID	20642897
Chemical and physical data
Formula	C15H18N2O2
Molar mass	258.321 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CCC2=C(C(C1)C(=O)OC)NC3=CC=CC=C23
InChI InChI=1S/C15H18N2O2/c1-17-8-7-11-10-5-3-4-6-13(10)16-14(11)12(9-17)15(18)19-2/h3-6,12,16H,7-9H2,1-2H3 Key:BYQISFIBSIGMLV-UHFFFAOYSA-N

See also

• Ibogalog
• Catharanthine
• Ibogainalog
• Ibogaminalog
• Noribogainalog
• PNU-22394
• Tabernanthalog